MEDNAX Inc. (NYSE:MD) went up by 5.88% from its latest closing price compared to the recent 1-year high of $34.19. The company’s stock price has collected 2.59% of gains in the last five trading sessions. Press Release reported on 07/15/21 that Mednax 2021 Second Quarter Conference Call/Webcast Scheduled for Friday, August 6, 2021
Is It Worth Investing in MEDNAX Inc. (NYSE :MD) Right Now?
MEDNAX Inc. (NYSE:MD) scored a price-to-earnings ratio above its average ratio, recording 173.86 x from its present earnings ratio. Plus, the 36-month beta value for MD is at 2.17. Opinions of the stock are interesting as 2 analysts out of 11 who provided ratings for MEDNAX Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 7 rated it as “hold,” and 1 as “sell.”
The average price from analysts is $29.56, which is -$1.73 below the current price. MD currently public float of 83.98M and currently shorts hold a 8.17% ratio of that float. Today, the average trading volume of MD was 646.17K shares.
MD’s Market Performance
MD stocks went up by 2.59% for the week, with a monthly drop of -2.97% and a quarterly performance of 12.96%, while its annual performance rate touched 60.27%. The volatility ratio for the week stands at 4.68% while the volatility levels for the past 30 days are set at 3.14% for MEDNAX Inc.. The simple moving average for the period of the last 20 days is -0.79% for MD stocks with a simple moving average of 19.56% for the last 200 days.
Analysts’ Opinion of MD
Many brokerage firms have already submitted their reports for MD stocks, with Stifel repeating the rating for MD by listing it as a “Hold.” The predicted price for MD in the upcoming period, according to Stifel is $30 based on the research report published on June 23rd of the current year 2021.
Deutsche Bank, on the other hand, stated in their research note that they expect to see MD reach a price target of $12, previously predicting the price at $20. The rating they have provided for MD stocks is “Sell” according to the report published on October 19th, 2020.
Citigroup gave a rating of “Neutral” to MD, setting the target price at $29 in the report published on January 03rd of the previous year.
MD Trading at -4.37% from the 50-Day Moving Average
After a stumble in the market that brought MD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -13.04% of loss for the given period.
Volatility was left at 3.14%, however, over the last 30 days, the volatility rate increased by 4.68%, as shares sank -6.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.38% lower at present.
During the last 5 trading sessions, MD rose by +2.59%, which changed the moving average for the period of 200-days by +82.62% in comparison to the 20-day moving average, which settled at $29.87. In addition, MEDNAX Inc. saw 21.15% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at MD starting from MEDEL ROGER MD, who sale 100,000 shares at the price of $25.40 back on Apr 01. After this action, MEDEL ROGER MD now owns 1,317,657 shares of MEDNAX Inc., valued at $2,540,321 using the latest closing price.
MEDEL ROGER MD, the Director of MEDNAX Inc., sale 100,000 shares at $23.66 during a trade that took place back on Jan 04, which means that MEDEL ROGER MD is holding 1,490,232 shares at $2,366,421 based on the most recent closing price.
Stock Fundamentals for MD
Current profitability levels for the company are sitting at:
- +9.92 for the present operating margin
- +24.27 for the gross margin
The net margin for MEDNAX Inc. stands at -0.55. The total capital return value is set at 5.86, while invested capital returns managed to touch -0.33.
Based on MEDNAX Inc. (MD), the company’s capital structure generated 241.44 points at debt to equity in total, while total debt to capital is 70.71. Total debt to assets is 53.90, with long-term debt to equity ratio resting at 238.61. Finally, the long-term debt to capital ratio is 69.88.
When we switch over and look at the enterprise to sales, we see a ratio of 1.51, with the company’s debt to enterprise value settled at 0.69. The receivables turnover for the company is 4.68 and the total asset turnover is 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.49.